
CBPE in exclusivity to acquire Palatine-backed Veincentre

Midmarket sponsor CBPE is in exclusivity to acquire Palatine-backed Veincentre, according to two sources familiar with the situation.
The owners of the varicose vein treatment clinics appointed Grant Thornton to explore a sale earlier this year, as reported. The company was due to be marketed off an EBITDA of GBP 5m-6m.
Palatine owned a substantial minority in Veincentre alongside its founders but the sale process was aiming to attract a majority investor, as reported. The sponsor first invested in 2019.
Veincentre has between 15-20 clinics across the UK, according to its website, and has opened eight new locations since Palatine’s investment, according to the sponsor’s website.
CBPE has invested widely across the healthcare sector with current portfolio assets including prosthetics manufacturer Blatchford and a minority stake in fertility clinic chain ARGC.
It sold Optima Health to Marlowe [LON: MRL] in January 2022 for a 6.5x return and Rodericks Dental to CapVest two months later.
Palatine and CBPE declined to comment. Grant Thornton did not immediately respond to a request for comment.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater